MedPath

Ibutamoren

Generic Name
Ibutamoren
Drug Type
Small Molecule
Chemical Formula
C27H36N4O5S
CAS Number
159634-47-6
Unique Ingredient Identifier
GJ0EGN38UL
Clinical Trials
Related News

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

Phase 3
Not yet recruiting
Conditions
Growth Hormone Deficiency (GHD)
Interventions
Other: Matched Placebo (Capsules)
First Posted Date
2025-04-29
Last Posted Date
2025-04-29
Lead Sponsor
Lumos Pharma
Target Recruit Count
150
Registration Number
NCT06948214

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)

Phase 2
Conditions
Growth Hormone Deficiency
Interventions
First Posted Date
2023-04-03
Last Posted Date
2024-02-15
Lead Sponsor
Lumos Pharma
Target Recruit Count
60
Registration Number
NCT05796440
Locations
🇦🇺

Canberra Hospital, Garran, Australian Capital Territory, Australia

🇺🇸

University of Iowa, Iowa City, Iowa, United States

🇺🇸

Seattle Children's Hospital, Seattle, Washington, United States

and more 4 locations

The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease

Phase 2
Completed
Conditions
NAFLD
Nonalcoholic Fatty Liver
NASH - Nonalcoholic Steatohepatitis
Interventions
First Posted Date
2022-05-06
Last Posted Date
2025-03-26
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
13
Registration Number
NCT05364684
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)

Phase 2
Active, not recruiting
Conditions
Growth Hormone Deficiency
Interventions
First Posted Date
2022-02-22
Last Posted Date
2024-02-02
Lead Sponsor
Lumos Pharma
Target Recruit Count
18
Registration Number
NCT05250063
Locations
🇺🇸

Nationwide Children's Hospital, Columbus, Ohio, United States

🇺🇸

The Children's Mercy Hospital, Kansas City, Missouri, United States

🇺🇸

Rady Children's Hospital, San Diego, California, United States

and more 7 locations

PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212)

Phase 2
Active, not recruiting
Conditions
Growth Hormone Deficiency
Interventions
First Posted Date
2021-03-19
Last Posted Date
2023-10-04
Lead Sponsor
Lumos Pharma
Target Recruit Count
24
Registration Number
NCT04806854
Locations
🇨🇱

Institute of Maternal and Child Research, University of Chile, Santiago, Chile

Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)

Phase 2
Completed
Conditions
Growth Hormone Deficiency
Interventions
First Posted Date
2020-11-04
Last Posted Date
2024-10-14
Lead Sponsor
Lumos Pharma
Target Recruit Count
82
Registration Number
NCT04614337
Locations
🇺🇸

The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

🇺🇸

Atlanta Diabetes Associates, Atlanta, Georgia, United States

🇺🇸

Children's National Hospital, Washington, District of Columbia, United States

and more 40 locations

Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects

Phase 2
Withdrawn
Conditions
Kidney Disease
Chronic Kidney Disease
Interventions
Drug: Placebo
First Posted Date
2011-04-28
Last Posted Date
2018-05-14
Lead Sponsor
University of Virginia
Registration Number
NCT01343641
Locations
🇺🇸

University of Virginia, Charlottesville, Virginia, United States

Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients

Not Applicable
Completed
Conditions
End Stage Renal Disease
Chronic Kidney Disease
Interventions
Drug: Placebo
First Posted Date
2006-11-02
Last Posted Date
2017-02-20
Lead Sponsor
University of Virginia
Target Recruit Count
49
Registration Number
NCT00395291
Locations
🇺🇸

University of Virginia, Charlottesville, Virginia, United States

Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)

Phase 2
Terminated
Conditions
Hip Fracture
First Posted Date
2005-08-09
Last Posted Date
2016-01-20
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
83
Registration Number
NCT00128115
Locations
🇳🇴

MSD (Norge) AS, Drammen, Norway

🇸🇪

Merck Sharp & Dohme (Sweden) AB, Sollentuna, Sweden

🇩🇪

Msd Sharp & Dohme Gmbh, Haar, Germany

and more 2 locations

Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia

Phase 2
Completed
Conditions
Fibromyalgia
Interventions
First Posted Date
2005-06-28
Last Posted Date
2012-08-06
Lead Sponsor
Bennett, Robert, M.D.
Target Recruit Count
64
Registration Number
NCT00116129
Locations
🇺🇸

Oregon Health & Science University, Portland, Oregon, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy